Alvotech (NASDAQ:ALVOW – Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 9,400 shares, a ...
The bioengineered protein drugs market is experiencing a paradigm shift, with pharmaceutical and biotech companies leveraging advanced biopharmaceuti ...
Biosimilars can not only reduce patients' financial burdens, but also encourage more people to go for early diagnosis and ...
Samsung Bioepis Co. and Celltrion Inc. are outpacing long-established global drug manufacturers such as Amgen Inc. and Sandoz ...
Number 5: The approvals for Celltrion's denosumab-bmwo (Stoboclo and Osenvelt) mark the third FDA green light for a ...
In a cohort of more than 11,000 patients from the U.K. and Ireland, a comparable proportion of new adalimumab users achieved ...
It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has ...
Looking ahead to 2025, Sandoz said it expects net sales to grow by a mid-single digit percentage in constant currencies.
According to a comprehensive report from The Insight Partners, "Health Economics and Outcome Research (HEOR) Services Market share and Forecast 2024 - ...
Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...
Pharmacy benefit managers take considerably different approaches to managing patient access to biosimilars, or cheaper ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results